natgillin/translations-raw huggingface dataset:
Detection of HER2 overexpression or HER2 gene amplification in gastric cancer Only an accurate and validated assay should be used to detect HER2 overexpression or HER2 gene amplification. 
Za otkrivanje povećane ekspresije HER2 ili HER2 genske amplifikacije potrebno je primjenjivati samo precizne i validirane metode.
Each 150 mg vial of Ontruzant is reconstituted with 7.2 mL of water for injections (not supplied). 
Sadržaj jedne bočice lijeka Ontruzant od 150 mg rekonstituira se sa 7,2 ml vode za injekcije (nije priložena u pakiranju).
DFS analysis was also performed at the final analysis of OS from the joint analysis of studies NSABP B-31 and NCCTG N9831. 
Analiza preživljenja bez bolesti također je provedena prilikom konačne analize ukupnog preživljenja iz skupne analize ispitivanja NSABP B--31 i NCCTG N9831.
Each 420 mg vial of Ontruzant is reconstituted with 20 mL of water for injections (not supplied). 
Sadržaj jedne bočice lijeka Ontruzant od 420 mg rekonstituira se s 20 ml vode za injekcije (nije priložena u pakiranju).
Treatment with AC→PH resulted in a statistically significant improvement in OS compared with AC→P (stratified HR=0.64; 95% CI [0.55, 0.74]; log-rank p-value <0.0001). 
(stratificirani omjer hazarda = 0,64; 95% CI [0,55; 0,74]; log-rang p-vrijednost <0,0001).
Formal cardiological assessment should be considered in patients in whom there are cardiovascular concerns following baseline screening. 
U bolesnika u kojih nakon početne procjene postoji sumnja na kardiovaskularnu bolest, potrebno je razmotriti formalnu kardiološku procjenu.
Ontruzant 150 mg powder for concentrate for solution for infusion 
Ontruzant 150 mg prašak za koncentrat za otopinu za infuziju
Tumour cell cluster with a faint⁄barely perceptible membranous reactivity irrespective of percentage of tumour cells stained 
Nakupina tumorskih stanica s vrlo slabom/jedva primjetnom membranskom reaktivnošću bez obzira na postotak obojenih tumorskih stanica
STATEMENT OF ACTIVE SUBSTANCE(S) The vial contains 420 mg trastuzumab. 
Bočica sadrži 420 mg trastuzumaba.
Ontruzant should be carefully handled during reconstitution. 
Tijekom rekonstitucije, lijekom Ontruzant treba rukovati oprezno.
In rare cases, a reduction in the amount of (amniotic) fluid that surrounds the developing baby within the womb has been observed in pregnant women receiving Ontruzant. 
U rijetkim je slučajevima u trudnica koje primaju Ontruzant primijećeno smanjenje količine
The recommended scoring system to evaluate the IHC staining patterns is as stated in Table 3: 
Preporučena ljestvica vrednovanja rezultata imunohistokemijskog bojenja preparata nalazi se u tablici 3:
The data also suggested that the pharmacokinetics of cisplatin were not affected by concurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab. 
Podaci su također ukazali na to da istodobna primjena kapecitabina ili istodobna primjena kapecitabina i trastuzumaba ne utječe na farmakokinetiku cisplatina.
in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. 
AC kemoterapije (AC→DH) ili u kombinaciji s docetakselom i karboplatinom (DCarbH).
A weak to moderate complete membrane staining is detected in >10% of the tumour cells. 
Slaba do umjerena obojenost cijele membrane u >10% tumorskih stanica.
The recommended maintenance dose at three-weekly intervals is 6 mg/kg body weight, beginning three weeks after the loading dose. 
Preporučena doza održavanja koja se primjenjuje u trotjednim intervalima iznosi 6 mg/kg tjelesne težine, a počinje se primjenjivati tri tjedna nakon udarne doze.
- intravenous 5-fluorouracil - 800 mg/m2/day as a continuous intravenous infusion over 5 days, given every 3 weeks for 6 cycles (days 1 to 5 of each cycle) Either of which was administered with: - cisplatin - 80 mg/m2 every 3 weeks for 6 cycles on day 1 of each cycle. 
- intravenski 5-fluorouracil - 800 mg/m² na dan u kontinuiranoj intravenskoj infuziji tijekom 5 dana, svaka 3 tjedna u 6 ciklusa (od 1. do 5. dana svakog ciklusa).
- Study BO16348 was designed to compare one and two years of three-weekly trastuzumab treatment versus observation in patients with HER2 positive EBC following surgery, established chemotherapy and radiotherapy (if applicable). 
U adjuvantnom je liječenju trastuzumab ispitivan u 4 velika multicentrična, randomizirana ispitivanja: - Ispitivanje BO16348 s ciljem usporedbe liječenja trastuzumabom u trotjednim ciklusima tijekom jedne i dvije godine i opservacije u bolesnika s HER2-pozitivnim tumorom dojke u ranom stadiju nakon kirurškog zahvata, završene kemoterapije i radioterapije (ako su provedeni).
• based on a loading dose of 8 mg trastuzumab/kg body weight, or a subsequent 3-weekly dose of 6 mg trastuzumab/kg body weight: Volume (mL) = 
• za udarnu dozu trastuzumaba od 8 mg/kg tjelesne težine ili daljnje trotjedne doze održavanja od 6 mg/kg tjelesne težine:
AC→D = doxorubicin plus cyclophosphamide, followed by docetaxel; AC→DH = doxorubicin plus cyclophosphamide, followed by docetaxel plus trastuzumab; CI = confidence interval Table 10 Overview of efficacy analyses BCIRG 006 AC→D versus DCarbH 
AC→D = doksorubicin i ciklofosfamid nakon kojih slijedi docetaksel; AC→DH = doksorubicin i ciklofosfamid nakon kojih slijede docetaksel i trastuzumab; CI = interval pouzdanosti
Table 6 Efficacy results from Study BO16348 Median follow-up 12 months* 
Tablica 6: Rezultati djelotvornosti iz ispitivanja BO16348
Uncommon side effects of Ontruzant (may affect up to 1 in 100 people): 
Manje česte nuspojave lijeka Ontruzant (mogu se javiti u do 1 na 100 osoba):
However, trastuzumab may elevate the overall exposure of one doxorubicin metabolite (7-deoxy-13 dihydro-doxorubicinone, D7D). 
Međutim, trastuzumab može povećati ukupnu izloženost jednome od metabolita doksorubicina
Table 2 Recommended scoring system to evaluate the IHC staining patterns in breast cancer 
Tablica 2: Preporučena ljestvica vrednovanja rezultata imunohistokemijskog bojenja preparata kod raka dojke Rezultat
Distant recurrence No. patients with event p<0.0001 
broj bolesnika s događajem p<0,0001
How Ontruzant is given 
Kako ćete primati Ontruzant
The recommended maintenance dose of Ontruzant at three-weekly intervals is 6 mg/kg body weight, beginning three weeks after the loading dose. 
Preporučena doza održavanja lijeka Ontruzant koja se primjenjuje u trotjednim intervalima iznosi 6 mg/kg tjelesne težine, a počinje se primjenjivati 3 tjedna nakon udarne doze.
CI) 
I
Common side effects of Ontruzant (may affect up to 1 in 10 people): 
Česte nuspojave lijeka Ontruzant (mogu se javiti u do 1 na 10 osoba):
Distant recurrence No. patients with event p=0.0008 
broj bolesnika s događajem p=0,0008
By comparison of simulated serum trastuzumab concentrations after trastuzumab monotherapy (4 mg/kg loading/2 mg/kg q1w intravenous infusion) and observed serum concentrations in Japanese women with HER2-positive MBC (study JP16003) no evidence of a PK effect of concurrent administration of docetaxel on the pharmacokinetics of trastuzumab was found. 
Usporedbom simuliranih koncentracija trastuzumaba u serumu nakon monoterapije trastuzumabom (udarna doza od 4 mg/kg / 2 mg/kg u intravenskoj infuziji jedanput tjedno) i opaženih koncentracija u serumu žena japanskog podrijetla s HER2-pozitivnim metastatskim rakom dojke (ispitivanje
Hazard ratio versus observation *Co-primary endpoint of DFS of 1 year versus observation met the pre-defined statistical boundary **Final analysis (including crossover of 52% of patients from the observation arm to trastuzumab) *** There is a discrepancy in the overall sample size due to a small number of patients who were randomized after the cut-off date for the 12-month median follow-up analysis 
***Postoji nesrazmjer u ukupnoj veličini uzorka zbog malog broja bolesnika koji su randomizirani nakon završnog datuma za analizu medijana praćenja od 12 mjeseci.
Instructions for reconstitution: 
POPIS POMOĆNIH TVARI Pomoćne tvari:
MBC EBC Table 15 Population predicted steady state PK exposure values (median with 5th - 95th percentiles) for trastuzumab intravenous infusion dosing regimens in MBC, EBC and AGC patients tumour type N Cmin,ss* Regimen Primary (µg/mL) 
Tablica 15: Vrijednosti farmakokinetičke izloženosti u stanju dinamičke ravnoteže predviđene za populaciju (medijan s rasponom od 5. do 95. percentila) uz režime doziranja intravenske formulacije trastuzumaba u bolesnika s metastatskim rakom dojke (MBC), ranim rakom dojke (EGC) i uznapredovalim rakom želuca (AGC)
Merck Sharp & Dohme B.V. Tel.: 0800 9999000 
Мерк Шарп и Доум България ЕООД Тел.: +359 2 819 3737
+Acute pulmonary oedema 
+dispneja kašalj epistaksa rinoreja
Weekly dosing in metastatic breast cancer The efficacy results from the monotherapy and combination therapy studies are summarised in Table 4: 
Rezultati djelotvornosti iz ispitivanja monoterapije trastuzumabom ili njegove primjene u kombiniranoj terapiji prikazani su u tablici 4:
Detection of HER2 overexpression or HER2 gene amplification in breast cancer Trastuzumab should only be used in patients whose tumours have HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay. 
Trastuzumab se smije primjenjivati samo u onih bolesnika s tumorima čije stanice pokazuju povećanu ekspresiju HER2 ili HER2 gensku amplifikaciju utvrđenu točnom i validiranom metodom.
Renal and urinary disorders Renal disorder 
babinje i perinatalno oligohidramnion nepoznato renalna hipoplazija nepoznato
Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration. 
Prije primjene, parenteralne lijekove treba vizualno pregledati da ne sadrže čestice ili da nisu promijenili boju.
Three-weekly dosing in metastatic breast cancer The efficacy results from the non-comparative monotherapy and combination therapy studies are summarised in Table 5: 
Rezultati djelotvornosti iz ispitivanja monoterapije i kombinirane terapije trastuzumabom bez kontrolnih skupina prikazani su u tablici 5:
The recommended scoring system to evaluate the IHC staining patterns is as stated in Table 2: 
Preporučena ljestvica vrednovanja rezultata imunohistokemijskog bojenja preparata nalazi se u tablici 2.
This yields a 7.4 mL solution for single-dose use, containing approximately 21 mg/mL trastuzumab, at a pH of approximately 6.0. 
Time se dobiva 7,4 ml otopine za jednokratnu primjenu koja sadrži približno 21 mg/ml trastuzumaba pH vrijednosti od približno 6,0.
This yields a 21 mL solution for single-dose use, containing approximately 21 mg/mL trastuzumab, at a pH of approximately 6.0. 
Time se dobiva 21 ml otopine za jednokratnu primjenu koja sadrži približno 21 mg/ml trastuzumaba pH vrijednosti od približno 6,0.
After a median follow-up of 12 months, the hazard ratio (HR) for disease free survival (DFS) was 0.54 (95% CI 0.44, 0.67) which translates into an absolute benefit, in terms of a 2-year disease-free survival rate, of 7.6 percentage points (85.8% versus 78.2%) in favour of the trastuzumab arm. 
(95% CI 0,44; 0,67), što znači da je apsolutno povoljan u smislu dvogodišnjeg preživljenja bez simptoma bolesti s razlikom od 7,6 postotnih bodova (85,8% naspram 78,2%) u korist skupine liječene trastuzumabom.
No disease-free survival (DFS) benefit was noticed in this subgroup of patients (hazard ratio=1.16, 95% CI [0.73, 1.83] for DCarbH (TCH) versus AC→D (AC→T); hazard ratio 0.97, 95% CI [0.60, 1.55] for AC→DH (AC→TH) versus AC→D). 
Nije primijećena prednost u pogledu preživljenja bez bolesti u toj podskupini bolesnika (omjer hazarda = 1,16; 95% CI [0,73; 1,83] za skupinu DCarbH (TCH),
Time to disease progression, median months 
Preživljenje bez progresije bolesti, medijan u mjesecima Vrijeme do progresije bolesti, medijan u mjesecima Stopa ukupnog odgovora na liječenje, %
A study conducted in lactating Cynomolgus monkeys at doses 25 times that of the weekly human maintenance dose of 2 mg/kg trastuzumab intravenous formulation demonstrated that trastuzumab is secreted in the milk. 
Ispitivanja provedena na makaki majmunima u razdoblju laktacije, kojima su davane doze intravenske formulacije trastuzumaba 25 puta veće od tjednih doza održavanja u ljudi od 2 mg/kg,
Trastuzumab washout period was assessed following q1w or q3w intravenous administration using the population PK model. 
Ispiranje trastuzumaba Razdoblje ispiranja trastuzumaba procijenjeno je nakon intravenske primjene lijeka jedanput na tjedan ili jedanput svaka 3 tjedna uz pomoć populacijskog farmakokinetičkog modela.
• difficulty in breathing when lying flat 
• otežano disanje u ležećem položaju • oštećenje/zatajenje jetre
The median overall survival for the high HER2-expressing group was 11.8 months versus 16 months, HR 0.65 (95% CI 0.51-0.83) and the median progression free survival was 5.5 months versus 7.6 months, HR 0.64 (95% CI 0.51-0.79) for FP versus FP + H, respectively. 
Medijan ukupnog preživljenja u skupini s visokom ekspresijom HER2 koja je primala fluoropirimidin i cisplatin iznosio je 11,8 mjeseci u usporedbi sa 16 mjeseci u skupini koja je uz fluoropirimidin i cisplatin primala i trastuzumab, omjer hazarda (HR) 0,65 (95% CI 0,51-0,83).
Slovenská republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com 
Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com
If left ventricular ejection fraction (LVEF) percentage drops ≥10 points from baseline AND to below 50%, treatment should be suspended and a repeat LVEF assessment performed within approximately 
Ako postotak ejekcijske frakcije lijeve klijetke (LVEF) padne za ≥10 bodova od početne vrijednosti
At 8 years, the disease-free survival rate was estimated to be 77.2% (95% CI: 75.4, 79.1) in the AC→PH arm, an absolute benefit of 11.8% compared with the AC→P arm. 
75,4; 79,1) u skupini liječenoj AC→PH kemoterapijom, što ukazuje na apsolutnu korist od 11,8% u usporedbi s liječenjem AC→P kemoterapijom.
Cardiac assessments, as performed at baseline, should be repeated every 3 months during treatment and every 6 months following discontinuation of treatment until 24 months from the last administration of trastuzumab. 
Kardiološke preglede, istovjetne onom obavljenom u sklopu početne procjene, potrebno je ponavljati svaka 3 mjeseca tijekom liječenja te svakih
Ontruzant treatment should only be initiated by a physician experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a healthcare professional only. 
Liječenje lijekom Ontruzant smije započeti samo liječnik s iskustvom u primjeni citotoksične kemoterapije
• Hypersensitivity to trastuzumab, murine proteins, or to any of the excipients listed in section 6.1 
• Preosjetljivost na trastuzumab, mišje proteine ili neku od pomoćnih tvari navedenih u dijelu 6.1. • Teška dispneja u mirovanju zbog komplikacija uznapredovale zloćudne bolesti ili zbog potrebe za dodatnom terapijom kisikom.
The population predicted PK exposure values (median with 5th-95th Percentiles) and PK parameter values at clinically relevant concentrations (Cmax and Cmin) for MBC, EBC and AGC patients treated with the approved q1w and q3w dosing regimens are shown in Table 14 (Cycle 1), Table 15 (steady-state), and Table 16 (PK parameters). 
Cmin) za bolesnike s metastatskim rakom dojke, ranim rakom dojke i uznapredovalim rakom želuca koji se liječe odobrenim režimima doziranja jedanput na tjedan i jedanput svaka 3 tjedna prikazane su u nastavku, u tablici 14 (1. ciklus), tablici 15 (stanje dinamičke ravnoteže) i tablici 16
Single doses of trastuzumab alone greater than 10 mg/kg have not been administered in the clinical trials; a maintenance dose of 10 mg/kg q3w following a loading dose of 8 mg/kg has been studied in a clinical trial with metastatic gastric cancer patients. 
Nisu ispitivane pojedinačne doze trastuzumaba više od 10 mg/kg; doza održavanja od 10 mg/kg svaka 3 tjedna nakon udarne doze od
Parenteral solutions should be inspected visually for particulates and discoloration prior to administration. 
Prije primjene, parenteralne otopine treba vizualno pregledati da ne sadrže čestice i da nisu promijenile boju.
Weak to moderate complete, basolateral or lateral membranous reactivity in ≥10% of tumour cells 
Slaba do umjereno potpuna, bazolateralna ili lateralna membranska reaktivnost u
Trastuzumab may persist in the circulation for up to 7 months after stopping trastuzumab treatment based on population pharmacokinetic analysis of all available data (see section 5.2). 
Na temelju populacijske farmakokinetičke analize svih dostupnih podataka (vidjeti dio 5.2),
Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (fluttering of the heart or a faster or slower heartbeat), seizures, vomiting or diarrhoea and tingling in the mouth, hands or feet. 
(lepršanje srca te ubrzani ili usporeni otkucaji srca), napadaje, povraćanje ili proljev te trnce u ustima, šakama ili stopalima.
in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. 
u kombinaciji s paklitakselom u liječenju bolesnika koji prethodno nisu primali kemoterapiju za metastatsku bolest i onih koji nisu pogodni za liječenje antraciklinom u kombinaciji s docetakselom u liječenju bolesnika koji nisu prethodno primali kemoterapiju za metastatsku bolest u kombinaciji s inhibitorom aromataze u liječenju postmenopauzalnih bolesnica s metastatskim rakom dojke pozitivnim na hormonske receptore, koje nisu prethodno liječene trastuzumabom.
following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel. 
Primjena u kombinaciji s paklitakselom ili docetakselom
For any other method that may be used for the assessment of HER2 protein or gene expression, the analyses should only be performed by laboratories that provide adequate state-of-the-art performance of validated methods. 
gena, analize je potrebno provoditi isključivo u laboratorijima koji raspolažu odgovarajućim, suvremenim validiranim metodama.
Merck Sharp & Dohme s.r.o. 
Slovenská republika Merck Sharp & Dohme, s. r. o.
in combination with neoadjuvant chemotherapy followed by adjuvant Ontruzant therapy, for locally advanced (including inflammatory) disease or tumours >2 cm in diameter (see sections 4.4 and 5.1). 
nakon adjuvantne kemoterapije doksorubicinom i ciklofosfamidom u kombinaciji s paklitakselom ili docetakselom u kombinaciji s adjuvantnom kemoterapijom koja uključuje docetaksel i karboplatin u kombinaciji s neoadjuvantnom kemoterapijom nakon koje slijedi adjuvantna terapija lijekom Ontruzant za lokalno uznapredovalu (uključujući upalnu) bolest ili tumore promjera >2 cm
Score Surgical specimen - staining pattern 
Kirurški uzorakkarakteristika obojenja
Ontruzant 150 mg powder for concentrate for solution for infusion Ontruzant 420 mg powder for concentrate for solution for infusion trastuzumab 
Uputa o lijeku: Informacije za korisnika Ontruzant 150 mg prašak za koncentrat za otopinu za infuziju Ontruzant 420 mg prašak za koncentrat za otopinu za infuziju trastuzumab
- intravenous docetaxel - 75 mg/m2 as an intravenous infusion over 1 hour, given every 3 weeks for 6 cycles (day 2 of cycle 1, then day 1 of each subsequent cycle) which was followed by: - carboplatin - at target AUC=6 mg/mL/min administered by intravenous infusion over 30-60 minutes repeated every 3 weeks for a total of six cycles 
Doksorubicin i ciklofosfamid su primijenjeni istodobno na sljedeći način: - brza intravenska injekcija doksorubicina u dozi od 60 mg/m2, svaka 3 tjedna, u 4 ciklusa - intravenski ciklofosfamid u dozi od 600 mg/m2 kroz 30 minuta, svaka 3 tjedna u 4 ciklusa.
Distant disease-free survival - No. patients with event - No. patients without event 
Post hoc eksplorativna analiza s preživljenjem bez bolesti i simptomatskim srčanim događajima Dugoročno praćenje**
- intravenous cyclophosphamide, at 600 mg/m2 over 30 minutes, given every 3 weeks for 4 cycles. 
- karboplatin - s ciljnom vrijednosti AUC = 6 mg/ml/min, primijenjen u intravenskoj infuziji tijekom 30-60 minuta, svaka 3 tjedna, ukupno 6 ciklusa.
Pulmonary hypoplasia 
Učestalost razdoblje pulmonalna hipoplazija nepoznato
Signs and symptoms of cardiac dysfunction such as dyspnoea, orthopnoea, increased cough, pulmonary oedema, S3 gallop, or reduced ventricular ejection fraction, have been observed in patients treated with trastuzumab (see section 4.4). 
pojačanog kašlja, plućnog edema, trećeg srčanog tona (S3) ili smanjene ejekcijske frakcije klijetke (vidjeti dio 4.4).
Patients with MBC or MGC should be treated with Ontruzant until progression of disease. 
U bolesnika s metastatskim rakom dojke ili metastatskim rakom želuca liječenje lijekom Ontruzant traje do progresije bolesti.
Rare side effects of Ontruzant (may affect up to 1 in 1000 people): 
Rijetke nuspojave lijeka Ontruzant (mogu se javiti u do 1 na 1000 osoba): • mišićna slabost
Score 
Rezultat
Staining pattern 
Uzorak bojenja
Vasodilatation 
ROK VALJANOSTI
• hair loss 
• poremećaji bubrega
Post-hoc exploratory analysis with DFS and symptomatic cardiac events Long term follow-up** hazard ratios (95% CI) A: doxorubicin; C: cyclophosphamide; P: paclitaxel; D: docetaxel; Carb: carboplatin; H: trastuzumab CI = confidence interval * At the time of the definitive analysis of DFS. 
A: doksorubicin, C: ciklofosfamid, P: paklitaksel, D: docetaksel, Carb: karboplatin, H: trastuzumab CI = interval pouzdanosti
In an exploratory subgroup analysis performed in the TOGA (BO18255) trial there was no apparent benefit on overall survival with the addition of trastuzumab in patients with ECOG PS 2 at baseline [HR 0.96 (95% CI 0.51-1.79)], non-measurable [HR 1.78 (95% CI 0.87-3.66)] and locally advanced disease [HR 1.20 (95% CI 0.29-4.97)]. 
(95% CI 0,87-3,66)] i lokalno uznapredovalom bolešću [HR 1,20 (95% CI 0,29-4,97)].
Pulmonary oedema 
Olof Palmestraat 10
• if you have (had) a benign or malignant tumour in the liver; 
• ako imate (ili ste imali) dobroćudni ili zloćudni tumor jetre;
It may harm them. 
Može im naškoditi.
What are you possibly suffering from? 
Od čega možda bolujete?
• if you smoke. 
• ako pušite.
• if you gave birth less than a few weeks ago 
• ako ste rodili prije manje od nekoliko tjedana
• if you are overweight; 
NAVOĐENJE DJELATNE(IH) TVARI
Not yet known 
Još nije poznato
Your risk is higher: 
Imate veći rizik:
The following two options can be followed. 
Možete slijediti sljedeće dvije opcije.
• VTE may be fatal in 1-2 % of cases. 
• VTE može imati smrtni ishod u 1-2% slučajeva.
Ask your doctor what to do if you are not sure when to start. 
Upitajte svog liječnika što da učinite ako niste sigurni kada početi.
1 will develop a VTE in one year. 
1 razviti VTE u godinu dana.
When should you contact your doctor? 
Kada se trebate obratiti svom liječniku?
Synonyms or related conditions are not listed, but should be taken into account as well. 
Sinonimi ili srodna stanja nisu navedeni, ali ih također treba uzeti u obzir.
The clinical relevance of this result is unknown. 
Klinička važnost tih rezultata nije poznata.
This allows you to check whether you took your daily tablet. 
Tako ćete moći provjeriti jeste li uzeli svoju dnevnu tabletu.
Recovery from blood clots is not always complete. 
Oporavak od krvnih ugrušaka nije uvijek potpun.
Changes generally remain within the normal laboratory range. 
Promjene se u pravilu zadržavaju unutar normalnih laboratorijskih raspona.
Particularly above 35 years 
Osobito iznad 35. godine
Particularly important to consider if other risk factors also present. 
Osobito je važno uzeti u obzir jesu li prisutni i drugi čimbenici rizika.
When and how to take the tablets 
Kako i kada uzimati tablete
Zoely will work immediately. 
Zoely će djelovati trenutno.
This means that you will always start a new blister on the same day of the week, and also that you have your period on roughly the same days each month. 
To znači da ćete uvijek počinjati s novim blisterom istog dana u tjednu te da ćete i mjesečnicu imati približno istih dana svakog mjeseca.